In April 2025, Terns enrolled the first patient in the dose expansion portion of the Phase 1 CARDINAL study of TERN-701 for CML. Patients will be randomized to one of two dose cohorts (320 mg or 500 ...

Continuous glucose monitoring can now spot early diabetes risks, offering a non-invasive alternative to traditional blood ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Daily variation in continuous glucose monitoring metrics was associated with cognitive performance among patients with type 1 diabetes.

We all know foods like pizza and ice cream aren’t good for our waistlines, but there are tasty alternatives that won’t pile ...

In a phase 3 study, orforglipron, a once-daily weight management candidate, delivered excellent results in patients with type 2 diabetes. The highest dose of the therapy led to a mean weight loss ...

Trump said he lost weight “the hard way ... GLP-1 receptor agonists are used to treat diabetes and obesity, and include Ozempic and Wegovy. GLP-1 would also make an excellent name for ...

American pharmaceutical company Eli Lilly and Company this week announced results from a late-stage clinical trial for its oral diabetes medicine, orforglipron. The once-daily pill, currently ...

For all the hype surrounding weight loss injections, including Ozempic and Mounjaro, the elephant in the slimming room remains: what happens when you stop taking the injections? Wellness coach ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a diabetes treatment since 2019. It's an orally available version of ...

and trials have shown participants had lower blood sugar and weight loss. If approved as a treatment for Type 2 diabetes and obesity, it could help tackle Britain’s weight problem. Last year ...

Orforglipron, a new nonpeptide GLP-1 drug, may provide easier access for the treatment of Type 2 diabetes and obesity without injections. According to early clinical trial results shared on ...